Fresenius Medical Care stock: UBS keeps EUR 36 target after Sell rating

Published on 10/21/2026 at 17:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 results arrive November 3, 2026. Fresenius Medical Care stock costs EUR 38.47 on October 21, 2026, down 2.26 percent versus the Xetra close.

Analyst target and reporting date

UBS kept a Sell rating and EUR 36.00 target on October 20, 2026.
Second-quarter 2026 revenue reached EUR 4.86 billion and adjusted operating income EUR 569.00 million.
Fresenius Medical Care stock costs EUR 38.47 at Lang & Schwarz on October 21, 2026 at 5:37 p.m. CEST, 2.26 percent below the Xetra close of October 20, 2026.
Fresenius Medical Care will publish third-quarter 2026 results on November 3, 2026.

Vintage Bauhaus-Poster mit geometrischem Tropfen-Motiv, Aufschriften BAD HOMBURG und CARE SINCE 1996 — Ein geometrisches Bauhaus-Poster im Stil der 1920er Jahre mit Tropfen-Motiv, den Aufschriften 'BAD HOMBURG' und 'CARE SINCE 1996' – eine stilisierte Hommage an den Firmensitz und das Gründungsjahr der Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) has a EUR 36.00 target and Sell rating from UBS, as MarketScreener reported on October 20, 2026. Fresenius Medical Care will publish third-quarter 2026 results on November 3, 2026, according to its investor calendar. The stock was trading at EUR 38.47 at Lang & Schwarz on October 21, 2026 at 5:37 p.m. CEST, down 2.26 percent versus the Xetra close of October 20, 2026 at EUR 39.36.

UBS target stays below the price

UBS retained its Sell rating and EUR 36.00 target on October 20, 2026. At EUR 38.47, the stock stood 6.86 percent above that target, calculated in the same currency. The analyst view therefore provides a concrete counterpoint to the company performance figures due before the next results date.

Stock position after the decline

Fresenius Medical Care was down 2.26 percent against the October 20 Xetra close by the Lang & Schwarz timestamp. The Xetra quote on October 20 reached EUR 39.73 at the high and EUR 39.33 at the low, with 8.01 million shares traded, while the 52-week range was EUR 34.57 to EUR 47.54.

The stock remained 19.08 percent below its 52-week high of EUR 47.54. Comdirect listed market capitalization at EUR 10.5 billion and the forward price-to-earnings ratio at 13.65 on October 20, 2026.

Q3 date follows stronger Q2

Fresenius Medical Care reported EUR 4.86 billion of revenue for the second quarter of 2026, up 1.40 percent from the second quarter of 2025. Adjusted operating income rose 23.00 percent at constant currency to EUR 569.00 million, according to StockWatch.

The November 3, 2026 report is the next scheduled corporate date. The investor calendar also lists a third-quarter financial report for November 6, 2026, giving investors two closely spaced reporting milestones.

Price and target define the near term

The market picture now combines a recent analyst target below the quote with a scheduled results date and a second-quarter operating improvement. The next report will provide the next measured comparison for revenue, operating income and the full-year outlook.

Fresenius Medical Care was trading at EUR 38.47 at Lang & Schwarz on October 21, 2026 at 5:37 p.m. CEST, 2.26 percent below the Xetra close of October 20, 2026 at EUR 39.36. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.